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, 2012; revised manuscript received March 1,Atrial ﬁbrillation (AF) is the most common cardiac
arrhythmia and is frequently observed in chronic heart
failure/reduced ejection fraction (HFREF) populations (1),
where the incidence is several-fold higher than in patients
without heart failure (2). In the Framingham cohort, new-
onset AF was associated with an increase in mortality in
patients with heart failure (3). However, in HFREF patients,
rhythm control strategies with current antiarrhythmic
medications have not been associated with improved
outcomes (4). This may be due to multiple adverse effects of
current antiarrhythmic agents in HFREF populations (5).
A drug treatment capable of decreasing the incidence of
new-onset AF with an improved safety proﬁle would beneﬁt
Abbreviations
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HFREF = heart failure with
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339HFREF patients, particularly if such therapy also favorably
affected the underlying pathophysiologic mechanisms that
predispose patients to AF. b-blockers are candidates for
such a therapy because they both improve heart failure
outcomes (6) and have efﬁcacy for AF prevention (7), likely
due in part to reverse remodeling in both ventricular (8) and
atrial (9,10) chambers. However, currently approved b-
blockers exhibit only modest efﬁcacy for reducing new-onset
AF in HFREF patients (7).
In patients with HFREF, the Arg389Gly polymorphism
in the b1-adrenergic receptor (-AR) (ADRB1) gene affects
the therapeutic response to bucindolol, a nonselective b-AR
blocker with sympatholytic properties (11). Compared to the
389 glycine (Gly) minor allele, the 389 arginine (Arg) major
allele gene protein product has a 3- to 4-fold higher signal
transduction capacity (11), higher afﬁnity for agonists
including norepinephrine (NE) (12), and a larger proportion
of constitutively active ARs (11). In a genetic substudy of the
BEST (Beta-Blocker Evaluation of Survival Trial), bucin-
dolol exhibited b1389 Arg/Gly genotype-dependent differ-
ential effects on mortality, heart failure hospitalizations, and
ventricular arrhythmias (11–13). In addition, in HFREF
patients who were b1389 Gly carriers (having at least one
copy of the dominant negative 389 Gly allele), an insertion/
deletion polymorphism at amino acid position 322–325 of the
a2c-AR, alleles commonly referred to as either wild type (Wt)
or deletion (Del), affects bucindolol’s response for both heart
failure (12,14) and ventricular arrhythmia (13) endpoints by
regulating bucindolol’s sympatholytic effects (14–16).
We hypothesized that b1389 Arg/Gly and a2c322–325
Wt/Del AR polymorphisms may modulate bucindolol’s
effects on new-onset AF in HFREF patients, as they do for
heart failure (12) and serious ventricular arrhythmia
endpoints (13).Methods
Study population. The BEST was a randomized trial of
bucindolol versus placebo in HFREF patients with NYHA
class III to IV heart failure and left ventricular ejection
fractions (LVEF) 0.35 (15). The current study analyzed
patients who were not in AF at study entry, including 2,176
patients in sinus rhythm (SR) plus 216 patients with
other rhythms to yield a study population of 2392 from the
entire 2,708 patient cohort, and 925 patients from the
1,040 DNA substudy (846 SR and 79 other rhythms). In
the 925 AF-free DNA bank substudy patients, the devel-
opment of new-onset AF was investigated in b1389 Arg/Gly
and a2c322–325 Wt/Del genetic subgroups as previously
described for heart failure (12) and ventricular arrhythmic
(13) endpoints. The BEST protocol, patient population, and
main outcomes have been previously described (15). The
DNA bank and the AR polymorphism substudy protocols
and patient populations have also been previously described
(11–14). This study used the DNA substudy of BEST,
a prospectively planned investigation (n ¼ 1,040) with aseparate consent form and ethical
committee review designed to
test the effects of AR poly-
morphisms on clinical outcomes.
All patients signed written
consent forms for both the parent
BEST protocol and the DNA
substudy. Although DNA anal-
ysis was performed after the trial
ended, clinical data remained
blinded from the investigators
until the coded genetic data
results were submitted to the data
coordinating center and analyzed
by trial statisticians.
The current substudy is a posthoc analysis investigating the incidence of new-onset AF.
Cases of AF were prospectively identiﬁed from adverse
event case report forms that included electrocardiograms
(ECGs) and were reviewed and certiﬁed by cardiologist
investigators at each site. In patients for whom no adverse
event had been recorded, new-onset AF event was also
obtained from study ECGs performed at baseline and at 3
and 12 months. In order to assess the total number of new-
onset AF events, the separate adverse event and study ECG
datasets were combined. Time of onset of the AF event was
taken as the day of detection, with the duration of AF-free
follow-up determined by comparison to the randomization
date.
Genotyping and norepinephrine measurements. Geno-
typing for b1389Arg/Gly and a2c322–325 Wt/Del poly-
morphisms was performed with archived DNA (11–14), and
plasma norepinephrine (NE) was measured from systemic
venous samples as previously described (16).
Statistical analysis. The primary analysis was the measure of
time to ﬁrst event of AF for patients free of AF at study entry.
A log rank statistic was used to generate treatment compar-
ison p values, and a Cox proportional hazards model was used
to estimate hazard ratios (HRs) and conﬁdence intervals (CIs)
between bucindolol and placebo groups. Per the study regu-
latory statistical analysis plan, all analyses were adjusted for
the covariates of presence/absence of coronary artery disease,
LVEF 20% to >20%, black and non-black race, and
gender, which are the 4 strata used in the treatment
randomized assignment. Follow-up was by intention-to-
treat, with censoring for cardiac transplantation, death,
nonfatal lost to follow-up, or study end on July 26, 1999. For
baseline characteristics, continuous variables were compared
using Student t test and presented as the mean  SD.
Categorical variables were compared using the chi-square test.
As previously reported (14), 66% of patients entered the
DNA substudy after randomization and had DNA collection
after being enrolled in the parent treatment protocol. In these
“late entry” patients, postrandomization AF events that
occurred prior to DNA collection were counted in the
statistical analysis.
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340Results
Clinical characteristics of patient cohorts. Baseline
characteristics for the entire 2,392 BEST AF-free cohort at
entry are given in Table 1, and they do not differ from
previously reported characteristics of the patients in SR at
study entry (17). The average follow-up of the 2,392 non-
AF patients was 2.0 years, with a maximum of 4.1 years.
Table 1 also gives the baseline characteristics of the 925
non-AF patients in the DNA substudy (average follow-up
2.1 years) and in selected genotype groups. The 69 patient
(b1389 Arg/Arg þ a2c322–325 Del carrier) group con-
tained too few events (n ¼ 6) for analysis, and the b1389
Arg/Arg group was therefore not subdivided by a2c322–325
Wt/Del polymorphism. In the DNA substudy, there were
441 patients who were b1389 Arg homozygotes (b1389
Arg/Arg) and 484 Gly carriers (b1389 Gly/Gly or Arg/Gly).
Within the b1389 Gly carrier patient group, 358 were a2c
Wt homozygotes and 126 were a2c322–325 Del carriers.
There were no clinically relevant differences between base-
line characteristics in the DNA substudy and the entire
cohort non-AF patients. As previously reported for all
baseline rhythms (12,13), there were signiﬁcant differences
in race and hypertension history between b1389 Arg/Arg
and Gly carriers groups, as well as between the 2 b1389 Gly
carrier/a2c322–325 groups that were related to the b1389
Gly and a2c322–325, deletion alleles being more prevalent in
blacks (11–14).
Outcomes in the BEST cohort and DNA substudy.
There were 190 new-onset AF events in the entire 2,392
patient cohort, for an overall event rate of 7.9%. In the 925
DNA substudy patients, there were 80 new-onset AF events
(rate, 8.6%). In the entire BEST cohort, there was a lower
incidence of new-onset AF in the bucindolol group than in
the placebo group (n ¼ 75 [6.2%] vs. n ¼ 115 [9.7%] HR:Table 1
Baseline Patient Characteristics for Patients Who Were Not








Age (yrs) 59.6  12.4 59.7  12.2 59.7  11.9
Male (%) 1,829 (76%) 718 (78%) 345 (78%)
Black (%) 586 (25%) 198 (21%) 63 (14%)
Resting HR
(beats/min)
82.5  13.4 81.7  13.4 81.5  13.7
HTN (%) 1,424 (60%) 523 (57%) 238 (54%)
Diabetes (%) 876 (37%) 333 (36%) 165 (38%)
Ischemic cause (%) 1411 (59%) 550 (59%) 259 (59%)
LVEF (%) 22.9  7.3 23.5  7.1 23.3  7.1
HF duration
(months)
48.2  47.9 45.1  47.4 47.8  51.3
NYHA class III (%) 2,200 (92%) 857 (93%) 418 (95%)
Digoxin (%) 2,197 (92%) 827 (89%) 398 (90%)
Values are mean  SD or n (%). p values for comparisons of genotype subgroups consist of chi-square tes
yp < 0.01; zp < 0.05.
AF ¼ atrial ﬁbrillation; Arg ¼ arginine; Del ¼ deletion; Gly ¼ glycine; HF ¼ heart failure; HR ¼ heart ra
Association; Wt ¼ wild type.0.59 [95% CI: 0.44 to 0.79]), corresponding to a 41% risk
reduction (Table 2). There was a similar decrease in the
incidence of new-onset AF in the DNA substudy in the
bucindolol group compared to the placebo group (n ¼ 31
[6.7%] vs. n ¼ 49 [10.7%]; HR: 0.57 [95% CI: 0.36 to
0.90]) (Table 2). Data presented in Table 2 indicate that
85% of events were detected from adverse event forms as
opposed to routine ECGs only; thus, most of the events
were symptomatic. Time to ﬁrst event curves for the entire
cohort and DNA substudy are given in Figure 1.
Table 3 gives the reduction in new-onset AF analyzed by
event duration. AF events were classiﬁed as short duration
paroxysmal (<24 h), longer duration paroxysmal (between
24 h and 7 days), or persistent (longer than 7 days). Greater
than two-thirds (67.9%) of the events were persistent AF,
with 23.2% of events longer paroxysmal and only 8.9% of
events being short paroxysmal. By HR, bucindolol treatment
effects were similar for the 3 AF durations, with HR of 0.51
(p ¼ 0.183), 0.57 (p ¼ 0.066), and 0.62 (p ¼ 0.007) for
shorter paroxysmal, longer paroxysmal, and persistent AF,
respectively (Table 3). However, event rates were low in the
paroxysmal groups, and the persistent AF group was the
only one that attained statistical signiﬁcance.
Outcomes by genotype group. Table 4 gives HR data by
genotype group. In the 441 b1389 Arg/Arg patients,
bucindolol was associated with a marked decrease in the
incidence of new-onset AF (HR: 0.26 [95% CI: 0.12 to
0.57], p ¼ 0.0003). In contrast, bucindolol had no impact
on the incidence of new-onset AF in the 484 b1389 Gly
carriers (HR: 1.01 [95% CI: 0.56 to 1.84], p ¼ 0.97). In the
time to ﬁrst event curves shown in Figure 2, the 74% risk
reduction by bucindolol in b1389 Arg/Arg patients was
associated with an early divergence of curves. There was no




b1 Gly carrier þ a2c Wt/Wt
(n ¼ 358)
b1 Gly carrier þ a2c Del
(n ¼ 126)
(p vs. Wt/Wt)
59.8  12.4 60.2  12.3 58.5  12.8
373 (77%) 281 (78%) 92 (73%)
135 (28%)* 47 (13%) 88 (70%)*
81.9  13.2 81.6  13.4 82.8  12.7
225 (59%) 191 (53%) 94 (75%)*
168 (35%) 120 (34%) 48 (38%)
291 (60%) 230 (64%) 61 (48%)y
23.7  7.1 23.9  7.1 23.0  7.1
42.7  43.4 41.5  42.5 46.3  45.7
439 (91%)z 325 (91%) 114 (90%)
429 (89%) 319 (89%) 110 (87%)
t results for categorical variables and the Wilcoxon test results for continuous variables. *p < 0.001;
te; HTN ¼ history of hypertension; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart
Table 2 Prevention of New-Onset Atrial Fibrillation by Bucindolol in BEST
Treatment Group
Patients Free of AF at Baseline
Assessed by ECG
Patients With New-Onset AF
Reported as AE During the Trial
Total No. of Patients With
New-Onset AF During the Trial
Entire cohort
Placebo (%) 1,190 (88.3%) 100 (8.4%) 115 (9.7%)
Bucindolol (%) 1,202 (89.2%) 61 (5.1%) 75 (6.2%)
Time to ﬁrst event of new-onset AF 0.55 (0.44 to 0.76), p ¼ 0.0002 0.59 (0.44 to 0.79), p ¼ 0.0004
DNA substudy
Placebo (%) 460 (88.0%) 45 (9.8%) 49 (10.7%)
Bucindolol (%) 465 (90.6%) 25 (5.4%) 31 (6.7%)
Time to ﬁrst event of new-onset AF 0.50 (0.31 to 0.82), p ¼ 0.005 0.57 (0.36 to 0.90), p ¼ 0.014
Values are n (%) or hazard ratio (95% conﬁdence interval), p value.
AE ¼ adverse event; AF ¼ atrial ﬁbrillation; BEST ¼ Beta-Blocker Evaluation of Survival Trial.
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341received bucindolol compared to placebo. These results
yielded a signiﬁcant statistical interaction (p ¼ 0.008)
between treatment and b1389 Arg/Gly genotypes.
For both heart failure endpoints (12) and serious
ventricular arrhythmias (13), when HFREF patients are
b1389 Gly carriers, the type of associated a2c322–325 Wt/
Del polymorphism can alter bucindolol treatment effects.
Data in Table 4 suggest this is also the case for prevention of
AF, where Del carriers have a HR >1.0. Moreover, the 3-
genotype group construct that included b1389 Arg/Arg
patients had an interaction p value of 0.016, supporting the
validity of subdividing the b1389 Gly carrier group by a2c
polymorphism.
Plasma norepinephrine and new-onset AF. In order to
assess the relationship of adrenergic drive and outcomes,
systemic venous plasma NE levels were measured at baselineFigure 1 Time to New-Onset AF in Bucindolol and Placebo Arms of B
Time to event curves for new-onset atrial ﬁbrillation (AF) in the BEST entire cohort (A) and theand at months 3 and 12. Of the entire 2,392 patient cohort,
1,868 had baseline NE measured. Compared to patients who
remained free of AF, patients who developed AF had higher
baseline NE levels in the bucindolol group (581 304 pg/ml
vs. 514  344 pg/ml, respectively, p ¼ 0.009) and in the
combined treatment groups (530 231 pg/ml vs. 498 326
pg/ml, respectively, p ¼ 0.015). Bucindolol produced
a signiﬁcant reduction in NE levels at 3 months in patients
who developed AF (by 129  49 pg/ml, p ¼ 0.0009 vs.
placebo change) and in patients who remained free of AF (by
74  12 pg/ml, p <0.0001 vs. placebo change), with no
differences between the 2 groups (p ¼ 0.23). Placebo-treated
patients exhibited increases in NE in both the new-onset AF
subgroup (by 88  46 pg/ml) and in patients who remained
free of AF (by 21  11 pg/ml, p ¼ 0.29 vs. new-onset AF).
Table 4 gives NE changes at 3 months within theEST
DNA substudy (B). Dashed line¼ placebo; solid line ¼ bucindolol. HR¼ hazard ratio.
Table 3 Duration of New-Onset Atrial Fibrillation Events in BEST
Patient Group Total Placebo Total Bucindolol Hazard Ratio (95% CI)
Logrank
p Value
Entire cohort (n ¼ 2392), all AF 115/1,190 (9.7%) 75/1,202 (6.2%) 0.59 (0.44 to 0.79) 0.0004
<24 h (n ¼ 17 of 190 [8.9%]) 11/1,190 (0.9%) 6/1,202 (0.5%) 0.51 (0.19 to 1.39) 0.183
>24 h to 7 days (n ¼ 44 of 190 [23.2%]) 27/1,190 (2.3%) 17/1,202 (1.4%) 0.57 (0.31 to 1.05) 0.066
>7 days (n ¼ 129 of 190 [67.9%]) 77/1,190 (6.5%) 52/1,202 (4.3%) 0.62 (0.43 to 0.88) 0.007
Values are n/N (%).
AF ¼ atrial ﬁbrillation; BEST ¼ Beta-Blocker Evaluation of Survival Trial; CI ¼ conﬁdence interval.
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342pharmacogenetic subgroups, where it can be observed that
there are similar degrees of NE lowering in the bucindolol
b1389 Arg/Arg and Gly carrier genetic groups (respectively,
71 and 78 pg/ml and both p <0.010 vs. placebo change).
Within the Gly carrier group, the a2c322–325 Del carrier
subgroup has a large degree of bucindolol-associated NE
reduction (by 164 pg/ml) as previously reported for the full
1,040, all rhythms DNA substudy population (12), which is
due to the exclusive presence of the a2c322–325 Del carrier
genotype (14).Discussion
Treatment effects of bucindolol on new-onset AF in the
BEST entire cohort and the DNA substudy. The DNA
substudy and the entire cohort parent populations were very
similar in baseline characteristics, length of follow-up (2.0
vs. 2.1 years), overall event rates (respectively, 7.9% and
8.6%), and placebo event rates (respectively, 9.7% and
10.7%). Thus, there was no evidence that late entry of most
in the DNA substudy relative to their randomization dates
had any impact on the study population from the standpoint
of development of new-onset AF.
For new-onset AF, bucindolol demonstrated respective
risk reductions of 41% (p ¼ 0.0004) and 43% (p ¼ 0.014) in
the entire and DNA substudy cohorts of BEST. In placebo
controlled HFREF trials, the effect of b-blockade on AF
episodes by event duration has not been previously reported,
and we evaluated effects on both paroxysmal and persistent
AF. In the entire cohort the majority (68%) of AF episodes
were >7 days duration or persistent, exhibiting a 38%
reduction (p ¼ 0.007) by bucindolol. Shorter or paroxysmal
episodes of AF were not signiﬁcantly reduced, although theyTable 4
Prevention of New-Onset AF by Bucindolol in BEST by Genot
at 3 Months in Patients in Genetic Groups
Measure
(b1389Arg/Arg þ any a2C)*
(P ¼ 206, B ¼ 235)
(b1389Gly Car
(P ¼ 254,
HR (95% CI), no. of events, p value 0.26 (0.12 to 0.57)
36 events, p ¼ 0.0003
1.01 (0.56 to 1
44 events, p
NE change at 3 months (pg/ml) P ¼ 14  20
B ¼ 71  22
p ¼ 0.0013
P ¼ 31  22
B ¼ 78  24
p ¼ 0.0019
Data show prevention of new-onset atrial ﬁbrillation (AF) by bucindolol in BEST by genotype (hazard ratio [R
3 months in patients in genetic groups. *Member of 3-group construct tested for interaction.
B ¼ bucindolol; Del ¼ deletion; P ¼ placebo; Wt ¼ wild type; other abbreviations as in Table 1.had lower HRs than in the persistent group. Thus, there was
observational evidence of a bucindolol treatment effect
regardless of AF duration, and statistical signiﬁcance of
a favorable effect in persistent AF.
Pharmacogenetic treatment effects. Reduction in new-
onset AF was driven by a large bucindolol treatment effect
in patients with a b1389 Arg/Arg genotype who had a 74%
reduction (p ¼ 0.0003) when treated with bucindolol
compared to those treated with placebo. There was no
reduction in event rate (HR: 1.01) in bucindolol patients
who were b1389 Gly carriers, and the treatment  geno-
type group interaction p value was 0.008. Subdividing the
b1389 Gly carrier genotype by a2c322–325 Wt/Del geno-
type appeared to further differentiate bucindolol response as
it does for heart failure (12) and serious ventricular
arrhythmia (13) endpoints, with a signiﬁcant (p ¼ 0.016)
test for interaction when b1389 Arg/Arg patients were
included in the 3-group analysis. Although differences in
race and/or history of hypertension could have affected the
analysis between genotypes, the (b1389 Gly carrier þ
a2c322–325 Wt/Wt) group had prevalence rates for black
patients and cases of hypertension that were similar to those
of the b1389 Arg/Arg group but markedly different HRs
(0.94, p ¼ 0.84 and 0.26, p ¼ 0.0003, respectively). This
indicates that the differentially enhanced treatment effect of
bucindolol on AF prevention is mediated through b1389
Arg vs. Gly ARs and is not directly related to race or
history of hypertension.
There appears to be a class affect of b-blockers for reduc-
tion of new-onset AF in HFREF patients. A meta-analysis
by Nasr et al. (7) of new-onset AF in HFREF trials
demonstrated an average 27% reduction of new-onset AF for
ﬁve different b-blockers and evidence for a treatment effectype, Total Number of Events, and Norepinephrine Change
rier þ any a2C)
B ¼ 230)
(b1 Gly carrier þ a2c Wt/Wt)*
(P ¼ 183, B ¼ 175)
(b1 Gly carrier þ a2c Del)*
(P ¼ 71, B ¼ 55)
.84)
¼ 0.97
0.94 (0.48 to 1.82)
36 events, p ¼ 0.84
1.33 (0.32 to 5.64)
8 events, p ¼ 0.70
P ¼ 38  25
B ¼ 54  22
p ¼ 0.0039
P ¼ 7  45
B ¼ 164  79
p ¼ 0.23
], 95% conﬁdence interval [CI]), total number of events, and p value. Norepinephrine (NE) change at
Figure 2 Time to New Onset by b1389 Arg/Gly Genotype
Time to event curves are shown for new-onset AF in the BEST DNA substudy by b1389 Arg/Gly genotype. There is a signiﬁcant interaction between genotype and treatment. The
beneﬁt of bucindolol is seen exclusively in the b1389 Arg/Arg genotype (A), with a risk reduction of 74% compared to placebo (p ¼ 0.008 for interaction vs. Gly carrier group).
(B) There was no impact of bucindolol in the b1 Gly carriers compared to placebo. Dashed line ¼ placebo; solid line ¼ bucindolol. Abbreviations as in Figure 1.
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343for all b-blockers except nebivolol. This relatively modest
reduction in new-onset AF across all b-blocker HFREF trials
is in contrast to the marked 74% reduction in new-onset
events in the b1389 Arg/Arg group observed in this analysis.
Role of adrenergic drive in the development of new-onset
AF and the pharmacotherapeutic effects of bucindolol.
Patients who developed AF had higher baseline NE levels
than patients who remained free of AF, similar to data for
AF development in an animal model of heart failure (18).
Bucindolol’s well-known sympatholytic effects (14–16) were
observed in patients who developed AF and in those who
did not and to the same extent in patients with b1389 Arg/
Arg and b1389 Gly carrier genotypes. Thus, NE reduction
by bucindolol may play a role in its AF prevention effects,
but a difference in degree of sympatholysis does not explain
the highly selective therapeutic effects of bucindolol in
patients with the b1389 Arg/Arg genotype. In this genotype
patients express only the b1389 Arg receptor, which is the
“NE receptor” in the heart (12). A reduction in NE will
therefore have a selectively greater therapeutic effect in this
genotype, and patients are also protected from the adverse
effects of marked sympatholysis (12).
In the (b1389 Gly carrier þ a2c322–325 Del carrier)
group, relatively low prevalence (13.6% of the total)
combination genotype that exhibited a statistically insignif-
icant 33% numerical increase in new-onset AF, there was
a large reduction in NE due to the a2c322–325 Del carrier
polymorphism (12,14). The adverse affects of sympatholysis
(12,14,16) may have canceled any therapeutic effect of
bucindolol in b1389 Gly carriers and led to a nonsigniﬁcant
increase in AF in patients with a [b1389 Gly carrier þ
a2c322–325 Del carrier] genotype.Mechanisms of atrial ﬁbrillation prevention by bucindolol
as modulated by the b1389 Arg/Arg genotype. There are
multiple lines of evidence linking high levels of b1-adrenergic
signaling, as predicted for b1389 Arg/Arg homozygotes, to
the development of AF. Higher adrenergic activity has been
shown to increase the inducibility of AF in humans and dogs
in a dose-dependent manner (19,20), and in a model of
ischemic cardiomyopathy, dogs that developed AF had
higher NE levels (18). Furthermore, in isolated human right
atrial preparations, isoproterenol infusion has been shown to
increase the frequency of atrial early and delayed after-
depolarizations, phenomena that have been implicated in
initiating AF (21). Bucindolol is especially effective in
inhibiting signaling through b1389 Arg ARs, through the
novel mechanisms of facilitating inactivation of constitutively
active receptors (the property of inverse agonism) (11) and
NE lowering (12), as well as through high-afﬁnity compet-
itive antagonism (6).
Study limitations. The primary limitation of the current
substudy is the post hoc nature of the analysis. AF was not
a prespeciﬁed efﬁcacy endpoint, and the data were not adju-
dicated but rather collected from investigator-reviewed
adverse event case report forms and serial ECGs, similar to
the approach used by van Veldhuisen et al. (22). Thus, some
AF events were likely missed, and in the case of the 15% of
events that were detected by ECG, only the onset of AF could
have been much earlier than the recorded date. On the other
hand, using adverse event forms and ECGs to capture new-
onset AF events represented a blinded, nonbiased way to
assess arrhythmia occurrence with 85% of the events being
symptomatic. Based on the use of adverse event case report
forms and ECGs, it is likely that most AF events of more than
Aleong et al. JACC: Heart Failure Vol. 1, No. 4, 2013
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344several hours duration were detected, with the onset con-
temporaneous to detection in a substantial majority of cases.
Another limitation of the current analysis is the relatively
small number of new-onset AF events. Although the entire
cohort contained 190 events, the largest number reported in
any HFREF b-blocker trial (7), the DNA substudy had only
80 events, and after pharmacogenetic subgrouping the
number of events in each group was further reduced by
w50%. These limitations will be addressed in a planned
study of AF prevention in b1389 Arg/Arg genotype
HFREF patients who are randomized to bucindolol versus.
metoprolol, a b-blocker that does not exhibit pharmacoge-
netic modulation of clinical therapeutic responses (23).
Conclusions
Bucindolol was associated with a signiﬁcant, quantitatively
large decrease in new-onset AF in the entire BEST cohort
that was observed exclusively in the b1389 Arg/Arg
genotype.
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